New oral therapy may help ease sarcoidosis affecting the skin
Treatment led to clearer skin for over two-thirds of trial's participants
Written by |
Full results from the Phase 2 part of an ongoing clinical trial showed "striking results" with the oral therapy brepocitinib in people with sarcoidosis affecting the skin. (Image from iStock)
In a large, ongoing clinical trial, a high dose of the oral therapy candidate brepocitinib was found to markedly reduce disease activity in most people with cutaneous sarcoidosis — a type of the rare autoimmune disease that affects the skin and currently has no approved treatment options.
In fact, by the end of the study’s Phase 2 portion, about 70% of participants given that high dose had clear or almost clear skin on a measure of cutaneous sarcoidosis activity.
That’s according to full results — called “striking” by one researcher — from the U.S.-based Phase 2 part of the BEACON clinical trial (NCT06978725). The findings were detailed in a study titled “Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis A Phase 2 Randomized Clinical Trial,” which was published in the journal JAMA Dermatology. The work was funded by therapy developer Priovant Therapeutics, a subsidiary of Roivant.
“Seeing clear or almost clear skin in more than two-thirds of patients on brepocitinib demonstrates dramatic improvement and was backed by multiple metrics showing this [treatment eased] patients’ symptoms and [improved] quality of life,” Misha Rosenbach, MD, the study’s first author at the University of Pennsylvania, said in a press release from Roivant. “This is the largest study in skin sarcoidosis to date, and the result [was] striking.”
Rosenbach added: “These published findings bring rigorous clinical evidence to a historically neglected disease and patient population and offer a compelling reason to believe that a fundamentally different future with more targeted, effective treatments may be possible for our patients.”
The trial’s ongoing Phase 3 portion, dubbed BEACON plus, is still recruiting participants at 44 sites across the U.S., the U.K. and Australia. That part of the study is designed to test brepocitinib’s high dose against a placebo for 16 weeks, or about four months, in an estimated 140 adults with cutaneous sarcoidosis.
Top-line results, or the first data from the trial, are anticipated in 2028, according to the developer.
BEACON plus trial now testing brepocitinib in more patients
Sarcoidosis is marked by abnormal clumps of immune cells that can form in various tissues throughout the body. In cutaneous sarcoidosis, these immune clumps affect the skin. Data from researchers in the U.S. suggest that this rare sarcoidosis type is more common in people of African descent than those from other ethnic groups.
“Cutaneous sarcoidosis is often on the face and severely impacts patients, and there are no approved treatments,” Rosenbach said.
Taken orally, brepocitinib is designed to reduce the activity of disease-driving immune cells by blocking the activity of two proteins, TYK2 and JAK1, important for immune activation.
The completed dose-finding Phase 2 portion of the BEACON study involved 31 people with cutaneous sarcoidosis, three-quarters of whom were Black individuals. These participants had lived with the condition for a mean of 8.1 years and had highly active disease, as reflected by a mean score of 33.6 on the Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) tool. CSAMI-A scores range from zero to 165, with higher scores reflecting more severe disease.
The participants were randomly assigned to take either 15 mg or 45 mg doses of brepocitinib or a placebo, once daily for about four months.
After four months on either dose of brepocitinib, CSAMI-A scores among participants decreased — meaning improved — by a mean of about 22 points. By contrast, among those given the placebo, average CSAMI-A scores dropped by less than one point. The researchers noted that the differences in score changes were statistically significant.
Moreover, significant differences between the high-dose and placebo groups were detected as early as one month, and were sustained at all time points thereafter.
By the end of the study, 69% of participants given brepocitinib’s higher dose had a Cutaneous Sarcoidosis Activity-Investigator Global Assessment (CSA-IGA) of clear or almost clear skin disease — essentially meaning little-to-no skin involvement — versus none of those on the placebo.
Additionally, more than three-quarters of patients in the high-dose group, and none of those in the placebo group, achieved a score reduction of at least 50% in CSAMI-A.
The researchers also noted that all patients on high-dose brepocitinib versus 14% of those on the placebo experienced a 10-point or greater CSAMI-A score reduction. That corresponds to twice the established minimum clinically important score difference, the team noted.
Low residual skin disease activity, as reflected by a CSAMI-A score below five, was also achieved by a significantly greater proportion of participants in the high-dose group relative to those in the placebo group (62% vs. 0%).
Outcomes with brepocitinib at the 15 mg dose “were consistently intermediate between those observed with brepocitinib, 45 mg, and [the] placebo, supporting a dose-dependent treatment effect,” the researchers wrote.
Subgroup analyses also supported dose-dependent benefits of brepocitinib among participants with lupus pernio, a difficult to treat form of cutaneous sarcoidosis.
Trial participants reported ‘improved’ outcomes with treatment
Patient-reported outcomes also consistently favored high-dose brepocitinib over the placebo. For example, in a measure of skin-related quality of life called the Skindex-16, scores improved by a mean of 23.5 points in the high-dose group and worsened by nearly nine points in the placebo group, according to the researchers.
The treatment was generally well tolerated, with no serious adverse events reported, per the team.
Overall, the researchers concluded that “brepocitinib demonstrated rapid, dose-dependent, and clinically meaningful improvements in [cutaneous sarcoidosis].” The team also noted “favorable effects on cutaneous remission-oriented efficacy [measures] and skin-related quality of life.”
According to the scientists, “patient-reported outcomes improved in parallel with clinician-assessed efficacy.”
Leave a comment
Fill in the required fields to post. Your email address will not be published.